Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.72% | -1.66% | +10.96% |
10/05 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
10/05 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.96% | 47Cr | |
+5.66% | 11TCr | |
+11.23% | 11TCr | |
-0.38% | 2.19TCr | |
-12.15% | 2.23TCr | |
-7.66% | 1.86TCr | |
-36.52% | 1.81TCr | |
-10.09% | 1.7TCr | |
+3.33% | 1.37TCr | |
+36.58% | 1.24TCr |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia